Loxo acquires BTK inhibitor program from Redx Pharma
Loxo Oncology Inc. paid $40mm to acquire Redx Pharma PLC’s preclinical Bruton’s tyrosine kinase (BTK) inhibitor program.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.